{"id":"NCT02395172","sponsor":"EMD Serono Research & Development Institute, Inc.","briefTitle":"Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)","officialTitle":"A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer That Has Progressed After a Platinum-Containing Doublet","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-24","primaryCompletion":"2017-11-22","completion":"2019-12-03","firstPosted":"2015-03-20","resultsPosted":"2018-12-13","lastUpdate":"2020-08-03"},"enrollment":792,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"Avelumab","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]}],"arms":[{"label":"Avelumab","type":"EXPERIMENTAL"},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study was to demonstrate superiority with regard to overall survival of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after failure of a platinum-based doublet.","primaryOutcome":{"measure":"Overall Survival (OS) Time in Programmed Death Ligand 1 (PD-L1) + Full Analysis Set Population (FAS)","timeFrame":"Time from date of randomization up to 1420 days","effectByArm":[{"arm":"Avelumab","deltaMin":11.4,"sd":null},{"arm":"Docetaxel","deltaMin":10.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.0721"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":10},"locations":{"siteCount":260,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Chile","Colombia","Croatia","Czechia","Denmark","France","Hungary","Israel","Italy","Japan","Mexico","Peru","Poland","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35771392","35144482","33636453","30262187"],"seeAlso":["http://clinicaltrials.emdgroup.com/en/trial-details/?id=EMR100070_004","http://medical.emdserono.com/en_US/home.html","http://www.merckgroup.com/en/company/contact-us/medinfo-contact-map.html"]},"adverseEventsSummary":{"seriousAny":{"events":167,"n":393},"commonTop":["Decreased appetite","Fatigue","Anaemia","Dyspnoea","Cough"]}}